Euronet Announces Appointment of Sergi Herrero to Its Board of Directors LEAWOOD, Kan., June 11, 2024 (GLOBE NEWSWIRE) -- Euronet (NASDAQ: EEFT), a leading global financial technology solutions and payments provider, today announced the appointment of Sergi Herrero to the Euronet Board of Directors effective June 4, 2024. His appointment increases the size of the board from nine to ten members. “We are extremely pleased to welcome Sergi to our board,” said Michael J. Brown, Euronet’s Chairman and Chief Executive Officer. “He has extensive C-level experience as an executive officer in t...
Adverum Biotechnologies Announces Appointments of Dr. Rabia Gurses Ozden as Chief Medical Officer and Dr. Szilárd Kiss as a Member of the Board of Directors REDWOOD CITY, Calif., June 11, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced the appointments of Dr. Rabia Gurses Ozden to the Company’s executive leadership team as chief medical officer and Dr. Szilárd Kiss to the Company’s Board of Directors. Dr. Ozden has stepped down ...
Moody's Ratings (Moody's) affirmed all ratings for CVR Partners, LP ("CVR"); including the B1 Corporate Family Rating ("CFR"), its B1-PD probability of default rating (PDR) and the B1 senior secured notes rating. Moody's also downgraded CVR's speculative grade liquidity rating to SGL-2 from SGL-1. T...
A director at Mueller Industries Inc sold 6,000 shares at 58.874USD and the significance rating of the trade was 50/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years c...
A director at Biohaven Ltd bought 28,000 shares at 35.580USD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...
Euronet Expands Malaysian Market Presence with the Acquisition of MEPS ATM Terminals from PayNet Euronet will acquire about 800 ATMs, making it the largest non-bank ATM terminal operator in Malaysia LEAWOOD, Kan., May 30, 2024 (GLOBE NEWSWIRE) -- Euronet (NASDAQ: EFFT), a leading global financial technology solutions and payments provider, announced today the completion of the acquisition of the Malaysian Electronic Payment System (MEPS) ATM terminals of Payments Network Malaysia Sdn Bhd (PayNet), the national payments network and central financial infrastructure for Malaysia. This ac...
IPG Photonics Launches LightWELD® 2000 XR Higher Power Enables Faster Speeds and Greater Productivity MARLBOROUGH, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- IPG Photonics (NASDAQ: IPGP), the world leader in fiber laser technology, today announced the launch of LightWELD 2000 XR, the fourth product offering within its handheld laser welding and cleaning product line. Fabricators will benefit from the increased processing speed and extended range of material thicknesses that LightWELD 2000 XR offers. More Power, More Productivity LightWELD 2000 XR is the new, superior version ...
eFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous Ovarian Cancer SOLANA BEACH, Calif. and REDWOOD CITY, Calif., May 20, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced a collaboration to conduct an investigator-sponsored trial (IST) evaluating zotatifin in combination with ...
Eyenovia Reports First Quarter 2024 Financial Results and Provides Updates on its Myopia Phase III Program and its Two FDA Approved Commercial Products, Mydcombi and Clobetasol Remains on track towards accelerating development of its late-stage product candidate in the multi-billion-dollar pediatric progressive myopia market, MicroPine Preparing for a 3Q 2024 launch of the first new ophthalmic steroid in 15 years, clobetasol propionate ophthalmic suspension 0.05%, for the treatment of inflammation and pain following ocular surgery Company to host conference call and webcast today, May 15t...
Eyenovia to Report First Quarter 2024 Results on Wednesday, May 15th Company to host an investor conference call and webcast at 4:30pm EDT NEW YORK, May 14, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: EYEN), an ophthalmic company with two FDA-approved products and a late-stage asset in pediatric progressive myopia, today announced that the Company will release financial results for the first quarter ended March 31, 2024 on Wednesday, May 15th, 2024, after the markets close. Following the release, Eyenovia management will host a conference call and webcast at 4:30 p.m. ET to review the financial ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.